Stock Analysis

Exploring Three High Growth Tech Stocks with Potential

As global markets navigate a period marked by stronger-than-expected U.S. labor market data and persistent inflation concerns, small-cap stocks have notably underperformed, with the Russell 2000 Index entering correction territory. In this environment of choppy market conditions and cautious investor sentiment, identifying high growth tech stocks involves looking for companies that demonstrate resilience through innovation and adaptability to shifting economic landscapes.

Advertisement

Top 10 High Growth Tech Companies

NameRevenue GrowthEarnings GrowthGrowth Rating
Yggdrazil Group30.20%87.10%★★★★★★
Ascelia Pharma76.15%47.16%★★★★★★
CD Projekt23.18%27.00%★★★★★★
Waystream Holding22.09%113.25%★★★★★★
AVITA Medical33.33%51.81%★★★★★★
Alkami Technology21.99%102.65%★★★★★★
Pharma Mar25.43%56.19%★★★★★★
TG Therapeutics30.33%44.07%★★★★★★
Elliptic Laboratories70.09%111.37%★★★★★★
Travere Therapeutics29.92%61.97%★★★★★★

Click here to see the full list of 1223 stocks from our High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Cafe24 (KOSDAQ:A042000)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Cafe24 Corp. operates a global e-commerce platform and has a market capitalization of approximately ₩886.13 billion.

Operations: The company generates revenue primarily from its Internet Business Solution segment, which accounts for ₩237.10 billion. Additional revenue streams include Transit and Clothing, contributing ₩44.06 billion and ₩22.16 billion respectively.

Cafe24, amidst a challenging tech landscape, showcases robust growth metrics that are commendable. With an annualized revenue increase of 11.3% and earnings growth soaring at 35.5%, the company outpaces the broader Korean market's averages of 9.2% and 29%, respectively. Significantly, its R&D investment strategy is aggressive, dedicating substantial resources to innovation—evidenced by a recent ₩13.4 billion spend on research activities which underscore its commitment to staying at the forefront of e-commerce solutions development despite some financial fluctuations due to one-off losses in the past year. This strategic focus not only fuels Cafe24's product enhancements but also positions it well for future technological advancements and market demands.

KOSDAQ:A042000 Earnings and Revenue Growth as at Jan 2025
KOSDAQ:A042000 Earnings and Revenue Growth as at Jan 2025

EuBiologics (KOSDAQ:A206650)

Simply Wall St Growth Rating: ★★★★★☆

Overview: EuBiologics Co., Ltd. is a biopharmaceutical company based in South Korea that specializes in providing vaccines for epidemics, with a market capitalization of ₩454.49 billion.

Operations: EuBiologics focuses on the development and provision of vaccines, generating revenue primarily from its pharmaceuticals segment, which totals ₩69.37 billion.

EuBiologics, navigating a competitive biotech landscape, has demonstrated impressive growth dynamics. The company's revenue surged by 21.9% annually, outstripping the broader market's expansion rate of 9.2%. This performance is bolstered by an aggressive R&D posture; last year alone saw R&D expenditures reach $50 million, representing a significant reinvestment into product development and innovation. These efforts are poised to keep EuBiologics at the forefront of vaccine development and disease prevention technologies, crucial in an era where healthcare resilience is paramount.

KOSDAQ:A206650 Revenue and Expenses Breakdown as at Jan 2025
KOSDAQ:A206650 Revenue and Expenses Breakdown as at Jan 2025

I'LL (TSE:3854)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: I'LL Inc. is a Japanese company specializing in system solutions, with a market capitalization of ¥64.35 billion.

Operations: The company focuses on providing system solutions in Japan, contributing to its market capitalization of ¥64.35 billion.

I'LL, amidst a tech landscape where innovation is paramount, has shown resilience with a steady annual revenue growth of 9.4%, outpacing the Japanese market's average of 4.2%. The company's commitment to advancement is evident in its R&D spending, which significantly contributes to its earnings growth forecast at 14.6% annually—surpassing the JP market forecast of 8%. This strategic focus on development is further underscored by I'LL's robust earnings quality and an impressive projected Return on Equity of 27.5% in three years, reflecting efficient reinvestment and operational prowess.

TSE:3854 Revenue and Expenses Breakdown as at Jan 2025
TSE:3854 Revenue and Expenses Breakdown as at Jan 2025

Summing It All Up

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if EuBiologics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About KOSDAQ:A206650

EuBiologics

A biopharmaceutical company, focuses on developing vaccines against global pandemic and bacterial vaccines primarily in South Korea.

Acceptable track record and slightly overvalued.

Advertisement

Weekly Picks

AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
65 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
FU
FundamentallySarcastic
CCP logo
FundamentallySarcastic on Credit Corp Group ·

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08

Fair Value:AU$12.6412.1% overvalued
11 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Updated Narratives

BO
MU logo
BonSquid88 on Micron Technology ·

Micron Technology will experience a robust 16.5% revenue growth

Fair Value:US$40021.1% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
AMZN logo
MarketMuse on Amazon.com ·

Amazon will rebound as AI investments start paying off by late 2026

Fair Value:US$45049.7% undervalued
45 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
RO
Robbo
HVN logo
Robbo on Harvey Norman Holdings ·

Inside Harvey Norman: Asset-Heavy Retail in an Online World

Fair Value:AU$5.8420.0% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.3% undervalued
65 users have followed this narrative
10 users have commented on this narrative
19 users have liked this narrative
AL
RKLB logo
AlexLovell on Rocket Lab ·

Early mover in a fast growing industry. Likely to experience share price volatility as they scale

Fair Value:US$16.25367.6% overvalued
68 users have followed this narrative
1 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0225.4% undervalued
1011 users have followed this narrative
6 users have commented on this narrative
28 users have liked this narrative